Nipro (FRA:5FA) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5FA Nipro Corp FRA:5FA
77 GF Score
Price €8.60
GF Value €7.83
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Nipro SpecialCharges?

Special Charges only applies to banks.

FRA:5FA
77GF Score
Nipro Corp FRA:5FA
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nipro (FRA:5FA) Overvalued in 2026?

Based on GuruFocus' analysis, Nipro stock appears to be overvalued. The current stock price of €8.60 is trading 9.8% above its estimated GF Value™ of €7.83. GuruFocus considers Nipro to be Fairly Valued.

Key valuation signals for FRA:5FA:

  • SpecialCharges:
  • GF Value™: €7.83 vs. price of €8.60 (9.8% above fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the FRA:5FA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nipro Business Description

Other Exchanges 8086:Japan
Address 3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
77GF Score

Get the complete analysis for FRA:5FA

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.60
Price
€7.83
GF Value